BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sagawa Y, Sato M, Sakai N, Chikahisa S, Chiba S, Maruyama T, Yamamoto J, Nishino S. Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin/orexin deficient narcoleptic mice. Neuropharmacology 2016;110:268-76. [PMID: 27474349 DOI: 10.1016/j.neuropharm.2016.07.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Urade Y. Neurobiological Basis of Hypersomnia. Sleep Medicine Clinics 2017;12:265-77. [DOI: 10.1016/j.jsmc.2017.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Takenoshita S, Nishino S. Pharmacologic Management of Excessive Daytime Sleepiness. Sleep Med Clin 2020;15:177-94. [PMID: 32386693 DOI: 10.1016/j.jsmc.2020.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
4 Takahashi T, Noriaki S, Matsumura M, Li C, Takahashi K, Nishino S. Advances in pharmaceutical treatment options for narcolepsy. Expert Opinion on Orphan Drugs 2018;6:597-610. [DOI: 10.1080/21678707.2018.1521267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R. Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretindeficient Rats: Preliminary Data. CNS Neurol Disord Drug Targets 2019;18:705-12. [PMID: 31642794 DOI: 10.2174/1871527318666191021143300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Takenoshita S, Nishino S. Pharmacologic Management of Excessive Daytime Sleepiness. Sleep Med Clin 2017;12:461-78. [PMID: 28778242 DOI: 10.1016/j.jsmc.2017.03.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
7 Williams RH, Tsunematsu T, Thomas AM, Bogyo K, Yamanaka A, Kilduff TS. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy. J Neurosci 2019;39:9435-52. [PMID: 31628177 DOI: 10.1523/JNEUROSCI.0311-19.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
8 Nishimon S, Yamaguchi M, Muraki H, Sakai N, Nishino S. Intraperitoneal injection of ginkgolide B, a major active compound of Ginkgo biloba, dose-dependently increases the amount of wake and decreases non-rapid eye movement sleep in C57BL/6 mice. Neurosci Lett 2020;722:134832. [PMID: 32050100 DOI: 10.1016/j.neulet.2020.134832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ahmad AS, Ottallah H, Maciel CB, Strickland M, Doré S. Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes. Sleep 2019;42:zsz073. [PMID: 30893431 DOI: 10.1093/sleep/zsz073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]